BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 729
- Registration Number
- NCT04908189
- Locations
- 🇨🇳
Local Institution - 0140, Pingxiang, Jiangxi, China
🇨🇳Local Institution - 0191, Shenyang, Liaoning, China
🇨🇳Local Institution - 0158, Baotou, Neimeng, China
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- Conditions
- Gastric/Gastroesophageal Junction AdenocarcinomaCarcinoma, Renal CellCervical CancerNon-Small-Cell Lung CancerUrothelial CarcinomaOvarian NeoplasmsMicrosatellite Stable Colorectal CancerSquamous Cell Carcinoma of Head and NeckTriple Negative Breast NeoplasmsPancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 905
- Registration Number
- NCT04895709
- Locations
- 🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 268
- Registration Number
- NCT04895696
- Locations
- 🇨🇳
Local Institution - 0196, Baoding, Hebei, China
🇺🇸Private Practice - Dr. Jefrey Lieberman, Decatur, Georgia, United States
🇺🇸Local Institution - 0100, Birmingham, Alabama, United States
A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04882150
- Locations
- 🇺🇸
Local Institution - 0002, Salt Lake City, Utah, United States
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
- Conditions
- Renal Allograft Recipients
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04877288
- Locations
- 🇺🇸
Local Institution - 0022, Hollywood, Florida, United States
🇺🇸Local Institution - 0045, Miami, Florida, United States
🇺🇸Local Institution - 0049, Atlanta, Georgia, United States
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT04877990
- Locations
- 🇺🇸
Local Institution - 0036, Shreveport, Louisiana, United States
🇯🇵Local Institution - 0026, Bunkyo-ku, Tokyo, Japan
🇺🇸Local Institution - 0002, Wyoming, Michigan, United States
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
- Conditions
- Lupus Erythematosus, DiscoidLupus Erythematosus, Subacute Cutaneous
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 75
- Registration Number
- NCT04857034
- Locations
- 🇲🇽
Local Institution - 0071, Mexico City, Mexico
🇨🇳Local Institution - 0022, Taipei, Taiwan
🇺🇸Local Institution - 0059, Saint Louis, Missouri, United States
A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan
- Conditions
- COVID-19
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9282
- Registration Number
- NCT04828772
- Locations
- 🇯🇵
Medical Data Vision, Tokyo, Japan
🇯🇵Local Institution, Minato-ku, Tokyo, Japan
A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan
- Conditions
- Psoriasis
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 114
- Registration Number
- NCT04826536
- Locations
- 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
- Conditions
- Non-Small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3102
- Registration Number
- NCT04825873
- Locations
- 🇨🇳
Local Institution, Shanghai, Shanghai, China